Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
US12286403B2 · kind B2 · utility
0Cited by
14References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 12, 2020 |
| Grant date | Apr 29, 2025 |
| Priority date | — |
| Expiry date | Nov 30, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07J43/003
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.